Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

FDA Approves Aficamten for Obstructive HCM

News Daily News

FDA Approves Aficamten for Obstructive HCM

December 29, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

April 15, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

April 15, 2024

Aficamten Delivers Positive Results in SEQUOIA-HCM

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

December 27, 2023

Top Heart Failure News of 2022

News Daily News

Top Heart Failure News of 2022

January 04, 2023

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

News Daily News

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

February 13, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.